Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$12.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 789.68% year-over-year to -$12.1 million; the TTM figure through Mar 2026 stood at $18.3 million (up 71.52% YoY), while the FY2025 annual figure was $29.0 million, up 117.64% from the prior year.
• Change in Accured Expenses was -$12.1 million for Q1 2026 at Crinetics Pharmaceuticals, down from $11.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.5 million in Q2 2025 to a low of -$12.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $3.2 million across 5 years, with a median of $4.1 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 866.13% in 2025, then slumped 789.68% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $4.1 million in 2022, then sank by 53.47% to $1.9 million in 2023, then jumped by 221.89% to $6.1 million in 2024, then soared by 82.73% to $11.2 million in 2025, then sank by 207.95% to -$12.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$12.1 million (Q1 2026), $11.2 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.